Global healthcare AI startup Qure.ai completes $65 million Series D funding round

Qure.ai, a global healthcare AI innovator, recently announced the completion of a $65 million Series D funding round.

The startup said the latest investment will expedite expansion into the US market and other geographies, increase investment into foundational AI models and enable complementary med-tech company acquisitions.

Qure.ai is headquartered in Mumbai and has offices in New York, London, and Dubai.

Who are the investors?

The Series D round saw the participation of new strategic and financial investors led by Lightspeed and 360 ONE Asset, joined by Merck Global Health Innovation Fund and Kae Capital.

Existing investors also participated in the round, including Novo Holdings, Health Quad, and TeamFund, the release notes.

What does Qure.ai do?

Founded in 2016 by Prashant Warier, Qure.ai aims to make healthcare more accessible and equitable globally. This has driven its AI solution development.

The startup said that its solutions are deployed in over 90 countries across 3000+ sites, powering the efficient identification and management of critical diseases. Qure.ai claims that it has 18 FDA-cleared indications, and its products are Class IIb certified per EU MDR regulations.

Leadership comments

“Qure.ai has become a trusted medical imaging AI partner to hospitals and healthcare organisations around the world. Our work is helping to unlock clinical efficiencies and drive up the standard of care delivered to patients in the focus areas of TB, Lung Cancer and Stroke”, said Prashant Warier, who is also the CEO of Qure.ai. 

“AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes to workforce resource constraints, not just in western societies like the US and Europe, but in developing nations too. We also collaborate with half of the top 20 Pharma and MedTech companies, including AstraZeneca, Medtronic, and J&J, to accelerate early diagnosis and timely treatment of diseases."